Cardiac Troponin – High-Sensitivity Troponin Assays
for Earlier Diagnosis of Myocardial Infarctions
Time is Muscle – Earlier MI Diagnosis with Sensitive Troponin Assays
The detection of a rise and/or fall of cardiac troponin (cTn) plays a key role in the earlier diagnosis of myocardial infarction (MI). Cardiac troponins are markers of myocardial necrosis, and, because of their high cardiac-specificity, are the preferred biomarker for the diagnosis of MI.
Reliable Answers for Critical Needs
As a recognized worldwide leader in CVD testing, Siemens Healthineers is the only company offering multiple solutions for cardiac troponin I (cTnI) testing that meet the current guidelines for MI diagnosis*. Siemens’ high-sensitivity troponin I assays provide clinical sensitivity and precision for earlier detection of necrosis and MI than less-precise assays.
Troponin
Preferred Biomarker of Cardiac Injury
Troponin is a complex of three contractile regulatory proteins, troponin C, T and I, that control the calcium mediated interactions between actin and myosin in cardiac and skeletal muscles.
- Troponin I and T are specific to cardiac muscles, unlike troponin C which is associated with both cardiac and skeletal muscles.
- Troponin C is not used in the diagnosis of myocardial damage.
- Both Troponin I and Troponin T are released into circulation at the time of injury following the same release pattern in the system. However, cardiac Troponin I is slightly more differentiated from skeletal Troponin I than cardiac Troponin T is from skeletal Troponin T.
Cardiac troponins are released into circulation in response to myocardial necrosis. As such, cardiac troponins are the preferred biomarkers for the detection of cardiac injury, and have long assisted physicians in improving diagnostic strategies for the effective management of patients with chest pain.
- Relatively non-specific markers of myocardial damage, such as creatine kinase (CK), creatine kinase-MB (CK-MB), and myoglobin (MYO), were used in diagnostic laboratories prior to the commercial release of the troponin assays.
- Numerous clinical studies on troponin have indicated its superior cardiac specificity in comparison to CK, CK-MB, or MYO.
- Troponin levels remain elevated in the blood longer than CK-MB or MYO, providing an extended diagnostic window for MI.
Share this page:
*Defined by the ESC/ACC committee as an imprecision level of ≤10% at the 99th percentile of normal.
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.